Shanghai Ninth People's Hospital
上海交通大学医学院附属第九人民医院
Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Shanghai Ninth People's Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌6 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
- Stomach cancer胃癌22 papers led
- Retinoblastoma视网膜母细胞瘤29 papers led
- Osteosarcoma骨肉瘤16 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
- Neuroblastoma神经母细胞瘤1 paper led
- Haemophilia A血友病 A1 paper led
- Fanconi anaemia范可尼贫血1 paper led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病0 papers led
- Osteogenesis imperfecta成骨不全症1 paper led
- Hirschsprung disease先天性巨结肠0 papers led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led
Not listed for: Hepatocellular carcinoma, Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Shanghai for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Circular RNA EFR3A promotes nasopharyngeal carcinoma progression through modulating the miR-654-3p/EFR3A axis.
- Long non-coding RNA PTPRG-AS1/microRNA-124-3p regulates radiosensitivity of nasopharyngeal carcinoma via the LIM Homeobox 2-dependent Notch pathway through competitive endogenous RNA mechanism.
- Long noncoding RNA FAM225B facilitates proliferation and metastasis of nasopharyngeal carcinoma cells by regulating miR-613/CCND2 axis.
- Long Noncoding RNA CRNDE Functions as an Oncogene to Facilitate Aggressive Behaviors of Nasopharyngeal Carcinoma Cells by Modulating miR-3163/TWIST1 Axis.
- Expression of ANCR in nasopharyngeal carcinoma patients and its clinical significance.
- Long noncoding RNA ANCR promotes migration, invasion, EMT progress and stemness of nasopharyngeal carcinoma cells via the miR-4731-5p/NMT1 axis.
All its trials on ClinicalTrials.gov, any status2
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma.
- CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs.
- Expression of IDO1 in Tumor Microenvironment Significantly Predicts the Risk of Recurrence/Distant Metastasis for Patients With Esophageal Squamous Cell Carcinoma.
- Comprehensive analysis of transcriptome-wide m6A methylome in intermediate-stage Esophageal squamous cell carcinoma.
All its trials on ClinicalTrials.gov, any status1
Cancer
Stomach cancer
胃癌Led 22 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- Differential Rates of Early Gastric Cancer in the Urban and Rural Medical Centers of Hangzhou, China.
- Mapping immune trajectories from Helicobacter pylori gastritis to gastric cancer.
- Effect of food loop and duodenal stump fixation on clinical outcomes in patients undergoing radical gastrectomy with Roux-en-Y reconstruction for distal gastric cancer: a single-center propensity score matching analysis.
- Syphilitic gastritis resembling gastric cancer.
- A disappeared early gastric neoplasia.
- Huang-Jin-Shuang-Shen Decoction promotes CD8+ T-cell-mediated anti-tumor immunity by regulating chemokine CXCL10 in gastric cancer.
- Influence of lymph node removal on the prognosis of high malignancy potential gastric gastrointestinal stromal tumors: Insights from population-based study.
- Long-term survival outcomes of endoscopic therapy vs. surgical resection in patients with cardia gastrointestinal stromal tumor.
- Sustained silence of a small signet ring cell carcinoma.
- Calcifying fibrous tumor and pathological analysis.
- An unusual case of gastric ulcers.
- Overexpression of Integrin alpha V (ITGAV) in gastric cancer and its prognostic significance.
- A rare case of gastric submucosal eminence arising from calcified fibrous tumor.
- Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.
- High-grade intraepithelial neoplasia of the cervical esophagus arising from a tiny ectopic gastric mucosa.
- An unusual cause of a protuberant lesion of the gastric antrum.
- An unusual protuberant lesion in the gastric body.
- IL-6/IL-10 mRNA expression ratio in tumor tissues predicts prognosis in gastric cancer patients without distant metastasis.
- Hsa-miR-30a-3p attenuates gastric adenocarcinoma proliferation and metastasis via APBB2.
- Hsa_circ_0008434 regulates USP9X expression by sponging miR-6838-5p to promote gastric cancer growth, migration and invasion.
- Positive feedback between ROS and cis-axis of PIASxα/p38α-SUMOylation/MK2 facilitates gastric cancer metastasis.
- Bibliometric Evaluation of Publications (2000-2020) on the Prognosis of Gastric Cancer.
All its trials on ClinicalTrials.gov, any status2
Cancer
Retinoblastoma
视网膜母细胞瘤Led 29 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 9.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led29
- Status of and factors influencing paternal fatigue in children with retinoblastoma: a cross-sectional study.
- Factors influencing delayed medical treatment in children with retinoblastoma: a qualitative study.
- Anxiety, depression and fear of disease progression among Chinese parents of children with retinoblastoma.
- Lactylation-boosted polycomb repression of KLF4 elicits glycolysis in retinoblastoma: A positive feedback circuit between histone modifications.
- Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma.
- Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma.
- Increased clinical risk factors and absence of leucocoria in late-onset retinoblastoma: a comparative cohort study.
- Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients.
- Does vitreous haemorrhage and calcification lead to increased risk of enucleation in advanced retinoblastoma?
- Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management.
- Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial.
- Factors influencing parental fatigue in children with retinoblastoma based on the unpleasant symptoms theory.
- Risk factors for cataract in retinoblastoma management.
- Correlating somatic copy number alteration in aqueous humour cfDNA with chemotherapy history, eye salvage and pathological features in retinoblastoma.
- NSUN2-mediated m5 C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression.
- Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies.
- The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.
- A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of multiple oncogenes.
- Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial.
- Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes.
- Novel insights into RB1 mutation.
- Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.
- Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma.
- Monitoring Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting.
- Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy.
- Hope level and associated factors among parents of retinoblastoma patients during COVID-19 pandemic: a cross-sectional study.
- Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma.
- Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: A dual-center study of 145 patients.
- Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)4
- LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter.
- A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.
- Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.
- [Pay attention to the application of the international intraocular retinoblastoma classification and sequential multiple modality treatment].
All its trials on ClinicalTrials.gov, any status1
Cancer
Osteosarcoma
骨肉瘤Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led16
- Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.
- Cancer-associated fibroblasts in osteosarcoma: key players in immune escape and targeted therapy.
- Malignant transformation of craniofacial fibrous dysplasia: A clinicopathological, immunohistochemical and molecular analysis of 15 cases in one single institution.
- Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair.
- Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute.
- Photothermal-Triggered Extracellular Matrix Clearance and Dendritic Cell Maturation for Enhanced Osteosarcoma Immunotherapy.
- Head and Neck Osteosarcoma: Perineural Invasion is Associated With Disease-Free Survival and Tumor Metastasis.
- Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.
- DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1-Mediated NRF2 Ubiquitination.
- EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.
- Osteosarocma progression in biomimetic matrix with different stiffness: Insights from a three-dimensional printed gelatin methacrylamide hydrogel.
- Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP-2/Smad signaling pathway.
- Camouflage orthodontic treatment combined with genioplasty distraction osteogenesis for skeletal class II relationship secondary to osteosarcoma excision surgery.
- Ultrathin 2D Inorganic Ancient Pigment Decorated 3D-Printing Scaffold Enables Photonic Hyperthermia of Osteosarcoma in NIR-II Biowindow and Concurrently Augments Bone Regeneration.
- Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy.
- FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)22
- Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy.
- A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.
- P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
- SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.
- HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.
- Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
- Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.
- Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.
- Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.
- CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.
- Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
- MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.
- Baicalin induces apoptosis in human osteosarcoma cell through ROS-mediated mitochondrial pathway.
- The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.
- Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.
- Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways.
- Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.
- Post-operative hemimaxillectomy rehabilitation using prostheses supported by zygoma implants and remaining natural teeth.
- Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
- Osteosarcoma of head and neck: A retrospective study on prognostic factors from a single institute database.
- Osteosarcoma of the Mandible: A Site-Specific Study on Survival and Prognostic Factors.
- TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Influence of lymph node removal on the prognosis of high malignancy potential gastric gastrointestinal stromal tumors: Insights from population-based study.
- Long-term survival outcomes of endoscopic therapy vs. surgical resection in patients with cardia gastrointestinal stromal tumor.
- The impact of gender on survival outcomes in patients with small intestinal stromal tumors: a comprehensive analysis using the SEER database.
- A gastric bronchogenic cyst pre-operatively misdiagnosed as a gastrointestinal stromal tumor.
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)4
- MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
- Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.
- Association of microRNA 21 With Biological Features and Prognosis of Neuroblastoma.
- Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy.
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Fanconi anaemia
范可尼贫血Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Plasma apolipoprotein E protein attenuates pulmonary fibrosis through LRP1 and PLAU dual receptor-mediated TGF-β/Smad inhibition.
- Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.
- Exploring the role of PANoptosis in idiopathic pulmonary fibrosis based on scRNA-seq and bulk-seq.
- Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization.
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Osteogenesis imperfecta
成骨不全症Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hirschsprung disease
先天性巨结肠Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shanghai for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
上海交通大学医学院附属第九人民医院
Shanghai Ninth People's Hospital
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Suzhou Ninth People's Hospital; Ninth People's Hospital of Chongqing; Chongqing Ninth People's Hospital; Suzhou Ninth People's Hospital Affiliated to Soochow University; Huangpu Branch of the Ninth People's Hospital; Hangzhou Ninth People's Hospital; Bethel Hospital; 上海第九人民医院